Skip to main content

New Product Watch: Dec 16, 2008

Premium
CombiMatrix Molecular Diagnostics this week launched its ProScan test for prostate cancer.
 
The array comparative genomic hybridization-based ProScan test comprises probes for specific genomic loci of which copy number gains and losses have been shown to correlate with risk of recurrence and metastasis in patients post-prostatectomy, CMDX said.
 
The additional probes are an enhancement of the CMDX solid tumor array platform design which enables whole-genome tumor profiling, or genomic grading, while also providing information about the copy-number status of specific disease-associated loci, the firm said.
 
ProScan is available through CMDX’s CLIA-compliant lab in Irvine, Calif.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.